ReviewAnnals of coloproctology2021
Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer.
Review in Annals of coloproctology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Selective Macrocyclic WEE1 Kinase Inhibitors with Strong Efficacy against Patient-Derived Colorectal Cancer Organoids.Journal of medicinal chemistry · 2026Article
- Evolving therapeutics in colorectal cancer peritoneal metastases.Cancer metastasis reviews · 2026Review
- A Case Illustrating Challenges: Early-Onset Signet Ring Cell Rectal Carcinoma With Fulminant Peritoneal Progression.Clinical case reports · 2026Article
- Long-term outcomes of laparoscopic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: comparable with the open approach for limited colorectal peritoneal metastases (KNUCRC-25CR1).Surgical endoscopy · 2026Article
- Acral metastasis of colonic cancer: A case report.Qatar medical journal · 2026Article
- Oncologic outcomes of multivisceral resection for locally advanced colorectal cancer: a single-center retrospective cohort study.BMC surgery · 2025Article
- Molecular characterization of Pseudomyxoma peritonei with single-cell and bulk RNA sequencing.Scientific data · 2025Article
- Inflammatory and nutritional markers in colorectal cancer: Implications for prognosis and treatment.World journal of clinical oncology · 2024Article
- Comparison of EPIC Versus HIPEC in the Treatment of Colorectal Peritoneal Metastases and Appendix Tumors Using Inverse Probability of Treatment Weighting.Annals of surgical oncology · 2024Article
- Article
- CILP2 is a potential biomarker for the prediction and therapeutic target of peritoneal metastases in colorectal cancer.Scientific reports · 2024Article
- Article
- Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.Ewha medical journal · 2023Review
- Influence of the COVID-19 Pandemic on the Treatment Patterns and Outcomes of Colorectal Cancer.Ewha medical journal · 2023Review
- Effect of Intraperitoneal Chemotherapy with Regorafenib on IL-6 and TNF-α Levels and Peritoneal Cytology: Experimental Study in Rats with Colorectal Peritoneal Carcinomatosis.Journal of clinical medicine · 2023Article
- Fluorescence-guided colorectal surgery: applications, clinical results, and protocols.Annals of surgical treatment and research · 2023Review
- Article
- Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo.Annals of surgical oncology · 2022Article
- ASO Author Reflections: Is it Correct to Use 5% Dextrose Solution as a Carrier Fluid for Oxaliplatin-based HIPEC?Annals of surgical oncology · 2022Article
- Benign multicystic mesothelioma of appendiceal origin treated by hyperthermic intraperitoneal chemotherapy: A case report.International journal of surgery case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From the perspective of survival outcomes, the cancer survival of colorectal cancer (CRC) in the whole stage has improved. Peritoneal metastasis (PM) is found in approximately 8% to 15% of patients with CRC, with a poorer prognosis than that associated with other sites of metastases. Randomized controlled trials and up-to-date meta-analyses provide firm evidence that cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) could significantly improve overall survival compared with systemic chemotherapy alone in selected patients with CRC-PM. Practical guidelines recommend that the management of CRC-PM should be led by a multidisciplinary team carried out in experienced centers and consider CRS plus HIPEC for selected patients. In this review, we aim to provide the latest results of land mark studies and an overview of recent insights with regard to the management of CRC-PM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.